OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes
Harpinder Kaur, Nishant Shekhar, Saurabh Sharma, et al.
Pharmacological Reports (2021) Vol. 73, Iss. 3, pp. 736-749
Open Access | Times Cited: 87
Harpinder Kaur, Nishant Shekhar, Saurabh Sharma, et al.
Pharmacological Reports (2021) Vol. 73, Iss. 3, pp. 736-749
Open Access | Times Cited: 87
Showing 26-50 of 87 citing articles:
In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds
Maral Aminpour, Marco Cannariato, Jordane Preto, et al.
Computation (2022) Vol. 10, Iss. 4, pp. 51-51
Open Access | Times Cited: 16
Maral Aminpour, Marco Cannariato, Jordane Preto, et al.
Computation (2022) Vol. 10, Iss. 4, pp. 51-51
Open Access | Times Cited: 16
SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants
Almu’atasim Khamees, Jamal Bani-Issa, Mazhar Salim Al Zoubi, et al.
Pathogens (2022) Vol. 11, Iss. 2, pp. 275-275
Open Access | Times Cited: 15
Almu’atasim Khamees, Jamal Bani-Issa, Mazhar Salim Al Zoubi, et al.
Pathogens (2022) Vol. 11, Iss. 2, pp. 275-275
Open Access | Times Cited: 15
Extracellular binding sites of positive and negative allosteric P2X4 receptor modulators
Stephanie Weinhausen, Jessica Nagel, Vigneshwaran Namasivayam, et al.
Life Sciences (2022) Vol. 311, pp. 121143-121143
Closed Access | Times Cited: 14
Stephanie Weinhausen, Jessica Nagel, Vigneshwaran Namasivayam, et al.
Life Sciences (2022) Vol. 311, pp. 121143-121143
Closed Access | Times Cited: 14
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Asaf Biber, Michal Mandelboim, Geva Harmelin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 17
Asaf Biber, Michal Mandelboim, Geva Harmelin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 17
Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study
Suzan M. Mansour, Rehab Nabil Shamma, Kawkab A. Ahmed, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108004-108004
Open Access | Times Cited: 17
Suzan M. Mansour, Rehab Nabil Shamma, Kawkab A. Ahmed, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108004-108004
Open Access | Times Cited: 17
A comprehensive review and update on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Coronavirus disease 2019 (COVID-19): what do we know now in 2021?
Kamleshun Ramphul, Yogeshwaree Ramphul, Yun Park, et al.
Archives of Medical Science - Atherosclerotic Diseases (2021) Vol. 6, Iss. 1, pp. 5-13
Open Access | Times Cited: 16
Kamleshun Ramphul, Yogeshwaree Ramphul, Yun Park, et al.
Archives of Medical Science - Atherosclerotic Diseases (2021) Vol. 6, Iss. 1, pp. 5-13
Open Access | Times Cited: 16
In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease
Yuri Alves de Oliveira Só, Katyanna Sales Bezerra, Ricardo Gargano, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 755-755
Open Access | Times Cited: 2
Yuri Alves de Oliveira Só, Katyanna Sales Bezerra, Ricardo Gargano, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 755-755
Open Access | Times Cited: 2
Indian contribution toward biomedical research and development in COVID-19
Hardeep Kaur, Manpreet Kaur, Anusuya Bhattacharyya, et al.
Indian Journal of Pharmacology (2021) Vol. 53, Iss. 1, pp. 63-72
Open Access | Times Cited: 16
Hardeep Kaur, Manpreet Kaur, Anusuya Bhattacharyya, et al.
Indian Journal of Pharmacology (2021) Vol. 53, Iss. 1, pp. 63-72
Open Access | Times Cited: 16
A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory
Saloni Saloni, Dimple Kumari, Prabhat Ranjan, et al.
Structural Chemistry (2022) Vol. 33, Iss. 6, pp. 2195-2204
Open Access | Times Cited: 11
Saloni Saloni, Dimple Kumari, Prabhat Ranjan, et al.
Structural Chemistry (2022) Vol. 33, Iss. 6, pp. 2195-2204
Open Access | Times Cited: 11
Effectivity of repurposed drugs against SARS-CoV-2 infections, A hope for COVID 19: inhibitor modelling studies by docking and molecular dynamics
Pooja Yadav, Papia Chowdhury
Heliyon (2022) Vol. 8, Iss. 12, pp. e12327-e12327
Open Access | Times Cited: 11
Pooja Yadav, Papia Chowdhury
Heliyon (2022) Vol. 8, Iss. 12, pp. e12327-e12327
Open Access | Times Cited: 11
Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints
Marko Jukič, Katarina Kores, Dušanka Janežič, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 14
Marko Jukič, Katarina Kores, Dušanka Janežič, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 14
Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment
Amita Verma, Pradeep Kumar, Irine Pauly, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 46, pp. 3677-3705
Closed Access | Times Cited: 10
Amita Verma, Pradeep Kumar, Irine Pauly, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 46, pp. 3677-3705
Closed Access | Times Cited: 10
Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model
Takayuki Uematsu, Tomomi Takano, Hidehito Matsui, et al.
The Journal of Antibiotics (2023) Vol. 76, Iss. 8, pp. 481-488
Open Access | Times Cited: 5
Takayuki Uematsu, Tomomi Takano, Hidehito Matsui, et al.
The Journal of Antibiotics (2023) Vol. 76, Iss. 8, pp. 481-488
Open Access | Times Cited: 5
From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, Then Clot Blood Cells in Pulmonary and Systemic Microvasculature
David Scheim
SSRN Electronic Journal (2020)
Closed Access | Times Cited: 14
David Scheim
SSRN Electronic Journal (2020)
Closed Access | Times Cited: 14
Can Anti-Parasitic Drugs Help Control COVID-19?
Yasin Panahi, Masoomeh Dadkhah, Sahand Talei, et al.
Future Virology (2022) Vol. 17, Iss. 5, pp. 315-339
Open Access | Times Cited: 7
Yasin Panahi, Masoomeh Dadkhah, Sahand Talei, et al.
Future Virology (2022) Vol. 17, Iss. 5, pp. 315-339
Open Access | Times Cited: 7
Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures
Bruna Raphaela Oliveira Silva, Wellington Francisco Rodrigues, Daniela Gomes Pires Abadia, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 7
Bruna Raphaela Oliveira Silva, Wellington Francisco Rodrigues, Daniela Gomes Pires Abadia, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 7
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID ‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Alireza Mirahmadizadeh, Ali Semati, Alireza Heiran, et al.
Respirology (2022) Vol. 27, Iss. 9, pp. 758-766
Open Access | Times Cited: 7
Alireza Mirahmadizadeh, Ali Semati, Alireza Heiran, et al.
Respirology (2022) Vol. 27, Iss. 9, pp. 758-766
Open Access | Times Cited: 7
Photo-mediated and advanced oxidative processes applied for the treatment of effluents with drugs used for the treatment of early COVID-19: Review
Louidi Lauer Albornoz, V.D. Soroka, M.C.A. Silva
Environmental Advances (2021) Vol. 6, pp. 100140-100140
Open Access | Times Cited: 8
Louidi Lauer Albornoz, V.D. Soroka, M.C.A. Silva
Environmental Advances (2021) Vol. 6, pp. 100140-100140
Open Access | Times Cited: 8
Prospective mode of action of Ivermectin: SARS-CoV-2
Vaishali M. Patil, Saroj Verma, Neeraj Masand
European Journal of Medicinal Chemistry Reports (2021) Vol. 4, pp. 100018-100018
Open Access | Times Cited: 8
Vaishali M. Patil, Saroj Verma, Neeraj Masand
European Journal of Medicinal Chemistry Reports (2021) Vol. 4, pp. 100018-100018
Open Access | Times Cited: 8
Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology
Yalan Zhou, Huizhen Wang, Yang Li, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8257-8257
Open Access | Times Cited: 6
Yalan Zhou, Huizhen Wang, Yang Li, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8257-8257
Open Access | Times Cited: 6
Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic
Ajay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology (2022) Vol. 34, Iss. 4, pp. 429-444
Open Access | Times Cited: 5
Ajay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology (2022) Vol. 34, Iss. 4, pp. 429-444
Open Access | Times Cited: 5
Recent advances in avermectin chemistry
Leonid G. Menchikov, М. Х. Джафаров, И. В. Заварзин
Russian Chemical Reviews (2022) Vol. 91, Iss. 9, pp. RCR5051-RCR5051
Closed Access | Times Cited: 5
Leonid G. Menchikov, М. Х. Джафаров, И. В. Заварзин
Russian Chemical Reviews (2022) Vol. 91, Iss. 9, pp. RCR5051-RCR5051
Closed Access | Times Cited: 5
Ivermectin: recent approaches in the design of novel veterinary and human medicines
Maiara Callegaro Velho, Diego Fontana de Andrade, Ruy Carlos Ruver Beck
Pharmaceutical Development and Technology (2022) Vol. 27, Iss. 8, pp. 865-880
Closed Access | Times Cited: 5
Maiara Callegaro Velho, Diego Fontana de Andrade, Ruy Carlos Ruver Beck
Pharmaceutical Development and Technology (2022) Vol. 27, Iss. 8, pp. 865-880
Closed Access | Times Cited: 5
Ivermectin-induced bacterial gut dysbiosis does not increase susceptibility to Pseudomonas aeruginosa lung infection but exacerbates liver damage
Thiago Caetano Andrade Belo, Natália Cristina de Melo Santos, Bianca Silva Souto, et al.
Microbes and Infection (2022) Vol. 25, Iss. 4, pp. 105080-105080
Open Access | Times Cited: 5
Thiago Caetano Andrade Belo, Natália Cristina de Melo Santos, Bianca Silva Souto, et al.
Microbes and Infection (2022) Vol. 25, Iss. 4, pp. 105080-105080
Open Access | Times Cited: 5
SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore
Dina Sweed, Eman Abdelsameea, Esraa A. Khalifa, et al.
Egyptian Liver Journal (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 7
Dina Sweed, Eman Abdelsameea, Esraa A. Khalifa, et al.
Egyptian Liver Journal (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 7
